Inari Medical, Inc. (NASDAQ:NARI – Get Rating) Director Donald B. Milder sold 7,000 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $80.78, for a total transaction of $565,460.00. Following the completion of the sale, the director now owns 3,206,614 shares in the company, valued at $259,030,278.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Inari Medical Stock Down 3.5 %
Inari Medical stock traded down $2.77 during mid-day trading on Wednesday, reaching $76.28. The company’s stock had a trading volume of 682,559 shares, compared to its average volume of 625,224. Inari Medical, Inc. has a 12 month low of $50.50 and a 12 month high of $100.00. The business’s 50 day simple moving average is $72.69 and its 200 day simple moving average is $76.52.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the business. Trustcore Financial Services LLC grew its position in shares of Inari Medical by 266.7% in the 1st quarter. Trustcore Financial Services LLC now owns 275 shares of the company’s stock valued at $25,000 after acquiring an additional 200 shares during the period. Parkside Financial Bank & Trust bought a new position in shares of Inari Medical in the 1st quarter valued at about $25,000. Fifth Third Bancorp bought a new position in shares of Inari Medical in the 2nd quarter valued at about $27,000. C M Bidwell & Associates Ltd. bought a new position in shares of Inari Medical in the 4th quarter valued at about $49,000. Finally, DB Wealth Management Group LLC bought a new position in shares of Inari Medical in the 1st quarter valued at about $54,000. Institutional investors own 67.90% of the company’s stock.
Analysts Set New Price Targets
Inari Medical Company Profile
Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.
- Get a free copy of the StockNews.com research report on Inari Medical (NARI)
- Agilent Technologies Proves Its Worth VS Illumina
- Lowe’s Stands Out Amid Q2 Retail Reports
- Target’s Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.